Usa hospital virus covid-19 Usa

Covid-19: FDA grants emergency access to Bellerophon’s INOpulse

Reading now: 771
www.pharmaceutical-technology.com

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates The US Food and Drug Administration (FDA) has provided emergency expanded access to Bellerophon Therapeutics’ INOpulse for Covid-19 treatment.

INOpulse is an inhaled nitric oxide (iNO) delivery system. NO is a naturally produced molecule that plays a key role in the immune response against pathogens and infections.

According to in-vitro studies, NO blocks the replication of severe acute respiratory syndrome-related coronavirus (SARS-CoV) while improving the survival of infected cells.

In a clinical study involving SARS-CoV patients, iNO led to improvements in arterial oxygenation and lung infiltrates, along with a decrease in the requirement for

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA